Scholar Rock Holding (SRRK) is back in focus after updating investors on an FDA warning letter sent to its manufacturing partner, Catalent Indiana, along with plans to resubmit its biologics license ...

This investor just walked away as Scholar Rock heads into a pivotal 2026—here’s what that means for long-term shareholders.

Scholar Rock Holding Corporation ( SRRK) Citi Annual Global Healthcare Conference 2025 December 3, 2025 1:00 PM EST ...

CAMBRIDGE, Mass., November 18, 2025--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to dramatically improving the lives of children and adults with spinal ...

In early December 2025, Scholar Rock reported that reported that the Novo Nordisk Bloomington, Indiana site (formerly Catalent Indiana LLC) received an FDA warning letter, while the company still ...

Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to dramatically improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe, and ...

On Tuesday, 18 November 2025, Scholar Rock (NASDAQ:SRRK) presented at the Jefferies London Healthcare Conference 2025, discussing both challenges and strategic initiatives. The company addressed a ...

Investing.com - BMO Capital has raised its price target on Scholar Rock (NASDAQ:SRRK) to $50.00 from $45.00 while maintaining an Outperform rating on the stock.

Fintel reports that on November 17, 2025, Barclays maintained coverage of Scholar Rock Holding (NasdaqGS:SRRK) with a Overweight recommendation. As of November 17, 2025, the average one-year price ...

Determining which patients should receive the treatment will still require individual risk-benefit assessments, experts say.